{"id":"bpn14770","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BPN14770 works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.","oneSentence":"BPN14770 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:27.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune diseases such as rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT07018492","phase":"PHASE1","title":"Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-08-30","conditions":"Hepatic Impairment","enrollment":32},{"nctId":"NCT07012005","phase":"PHASE1","title":"Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-08-25","conditions":"Renal Impairment","enrollment":14},{"nctId":"NCT05163808","phase":"PHASE2, PHASE3","title":"A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2022-03-29","conditions":"Fragile X Syndrome","enrollment":163},{"nctId":"NCT06717438","phase":"PHASE2","title":"Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shionogi","startDate":"2025-05-13","conditions":"Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder","enrollment":30},{"nctId":"NCT05367960","phase":"PHASE3","title":"An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tetra Discovery Partners","startDate":"2022-11-01","conditions":"Fragile X Syndrome","enrollment":314},{"nctId":"NCT07011992","phase":"PHASE1","title":"A Study to Assess the Effects of BPN14770 on Rosuvastatin","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-07-18","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05358886","phase":"PHASE3","title":"A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2022-11-01","conditions":"Fragile X Syndrome","enrollment":171},{"nctId":"NCT03817684","phase":"PHASE2","title":"Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2019-04-30","conditions":"Alzheimer's Disease","enrollment":255},{"nctId":"NCT03569631","phase":"PHASE2","title":"A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2018-07-09","conditions":"Fragile X Syndrome, FXS, Fra(X) Syndrome","enrollment":30},{"nctId":"NCT04044781","phase":"PHASE1","title":"A Phase 1, Open-Label, PET Study of T2310 & BPN14770","status":"WITHDRAWN","sponsor":"Tetra Discovery Partners","startDate":"2020-01-10","conditions":"To Determine Brain Target Occupancy of BPN14770","enrollment":""},{"nctId":"NCT03861000","phase":"PHASE1, PHASE2","title":"Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2019-03-12","conditions":"Depression","enrollment":3},{"nctId":"NCT03030105","phase":"PHASE1","title":"Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2017-01","conditions":"Alzheimer Disease","enrollment":38},{"nctId":"NCT02648672","phase":"PHASE1","title":"BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2015-12","conditions":"Alzheimer's Disease","enrollment":32},{"nctId":"NCT02840279","phase":"PHASE1","title":"A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2016-06","conditions":"Alzheimer's Disease","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zatolmilast"],"phase":"phase_2","status":"active","brandName":"BPN14770","genericName":"BPN14770","companyName":"Tetra Discovery Partners","companyId":"tetra-discovery-partners","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPN14770 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of autoimmune diseases such as rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}